The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 And TB 500: Background, Indications, Efficacy, And Safety GlobalRPH BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with RFK Jr pushes for FDA approval of BPC 157 peptide Eric Topol, MD posted on the topic LinkedIn